Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.

Authors:
Hamilton JD; Harel S; Swanson BN; Brian W; Chen Z and 10 more

Journal:
Clin Exp Allergy

Publication Year: 2021

DOI:
10.1111/cea.13954

PMCID:
PMC8362102

PMID:
34037993

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Clin Exp Allergy

Abbreviation: Clin Exp Allergy

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Anaphylaxis in Brazil between 2011 and 2019.
Tanno LK; Molinari N; Annesi-Maesano I and 2 more (2022) - Transparency Score: 3/6
Anti-phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with na…
Eide JG; Wu J; Stevens WW and 16 more (2022) - Transparency Score: 3/6
Association between allergic sensitization and intestinal parasite infection in schoolchildren in G…
Brandt O; Wegenstein B; Müller I and 12 more (2022) - Transparency Score: 3/6
Burden of allergic disease among ethnic minority groups in high-income countries.
Jones CJ; Paudyal P; West RM and 5 more (2022) - Transparency Score: 2/6
Efficacy of N-acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctiv…
de Blay F; Gherasim A; Domis N and 2 more (2022) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICTS OF INTEREST JDH, SH, ZC, NA, MA, AR, BS and MR are employees and shareholders of Regeneron Pharmaceuticals, Inc. NMHG is a prior employee and shareholder of Regeneron Pharmaceuticals, Inc. WB, MSR, NP and LM are employees and may hold stock and/or stock options in Sanofi. BG and GP are prior employees and may hold stock and/or stock options in Sanofi."

Evidence found in paper:

"Funding information"

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025